These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28236246)
1. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo. Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246 [TBL] [Abstract][Full Text] [Related]
2. [Expression and antitumor activity of fusion protein RGD-TRAIL in Pichia pastoris]. Wang XF; Chen SZ Yao Xue Xue Bao; 2015 May; 50(5):552-9. PubMed ID: 26234135 [TBL] [Abstract][Full Text] [Related]
3. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444 [TBL] [Abstract][Full Text] [Related]
4. Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells. Yao R; Sui A; Wang Z; Liu S; Zhou Q; Liu X; Zhang H Mol Med Rep; 2012 Dec; 6(6):1355-60. PubMed ID: 22965279 [TBL] [Abstract][Full Text] [Related]
5. Effects of ebv-miR-BART7 on tumorigenicity, metastasis, and TRAIL sensitivity of non-small cell lung cancer. Wang L; Liu LF; Zhou L; Liao F; Wang J J Cell Biochem; 2019 Jun; 120(6):10057-10068. PubMed ID: 30569505 [TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft. Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Fang F; Wang AP; Yang SF Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761 [TBL] [Abstract][Full Text] [Related]
9. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Qiu F; Hu M; Tang B; Liu X; Zhuang H; Yang J; Hua ZC Sci Rep; 2013 Dec; 3():3565. PubMed ID: 24356445 [TBL] [Abstract][Full Text] [Related]
10. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer. Zhu K; Fang W; Chen Y; Lin S; Chen X Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445 [TBL] [Abstract][Full Text] [Related]
11. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70. Zhou Y; Ma J; Zhang J; He L; Gong J; Long C Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121 [TBL] [Abstract][Full Text] [Related]
12. A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo. Rozanov D; Spellman P; Savinov A; Strongin AY PLoS One; 2015; 10(4):e0122980. PubMed ID: 25849628 [TBL] [Abstract][Full Text] [Related]
13. The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases. Liu R; Ma X; Wang H; Xi Y; Qian M; Yang W; Luo D; Fan L; Xia X; Zhou J; Meng L; Wang S; Ma D; Xi L J Mol Med (Berl); 2014 Feb; 92(2):165-75. PubMed ID: 24158182 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096 [TBL] [Abstract][Full Text] [Related]
15. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance. Rozga P; Kloska D; Pawlak S; Teska-Kaminska M; Galazka M; Bukato K; Pieczykolan A; Jaworski A; Molga-Kaczmarska A; Kopacz A; Badyra B; Kachamakova-Trojanowska N; Zolnierkiewicz O; Targosz-Korecka M; Poleszak K; Szymanik M; Zerek B; Pieczykolan J; Jozkowicz A; Grochot-Przeczek A Int J Cancer; 2020 Aug; 147(4):1117-1130. PubMed ID: 31863596 [TBL] [Abstract][Full Text] [Related]
16. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625 [TBL] [Abstract][Full Text] [Related]
17. Fused hydrophobic elastin-like-peptides (ELP) enhance biological activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Huang K; Duan N; Zou W; Zhang C; Lai Y; Shen P; Hua Z Protein Pept Lett; 2015; 22(11):1000-6. PubMed ID: 26299999 [TBL] [Abstract][Full Text] [Related]
18. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter]. Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959 [TBL] [Abstract][Full Text] [Related]
19. AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L. Pieczykolan JS; Kubiński K; Masłyk M; Pawlak SD; Pieczykolan A; Rózga PK; Szymanik M; Gałązka M; Teska-Kamińska M; Żerek B; Bukato K; Poleszak K; Jaworski A; Strożek W; Świder R; Zieliński R Invest New Drugs; 2014 Dec; 32(6):1155-66. PubMed ID: 25182378 [TBL] [Abstract][Full Text] [Related]
20. Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Huang K; Duan N; Zhang C; Mo R; Hua Z Sci Rep; 2017 Feb; 7():41904. PubMed ID: 28225020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]